Skip to main content Accessibility help
×
×
Home

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

  • Michael E. Thase (a1), A. Richard Entsuah (a2) and Richard L. Rudolph (a2)
Abstract
Background

It had been suggested that the antidepressant venlafaxine, which inhibits reuptake of both serotonin and (at higher doses) noradrenaline, may result in better outcomes than treatment with selective serotonin reuptake inhibitors (SSRIs).

Aims

To compare remission rates during treatment with SSRIs or venlafaxine.

Method

Data from eight comparable randomised, double-blind studies of major depressive disorder were pooled to compare remission rates (Hamilton Rating Scale for Depression score ≤ 7) during treatment with venlafaxine (n=851), SSRIs (fluoxetine, paroxetine, fluvoxamine; n=748) or placebo (four studies; n=446).

Results

Remission rates were: venlafaxine, 45% (382/851); SSRIs, 35% (260/748); placebo, 25% (110/446) (P < 0.001; odds ratio for remission is 1.50 (1.3–1.9), favouring venlafaxine v. SSRIs). The difference between venlafaxine and the SSRIs was significant at week 2, whereas the difference between SSRIs and placebo reached significance at week 4. Results were not dependent on any one study or the definition of remission.

Conclusions

Remission rates were significantly higher with venlafaxine than with an SSRI.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
      Available formats
      ×
Copyright
Corresponding author
Michael E. Thase, Professor of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213-2593, USA
Footnotes
Hide All

Declaration of interest

M.E.T is a paid consultant to Wyeth–Ayerst Laboratories, the employer of A.R.E. and R.L.R.

Footnotes
References
Hide All
Alves, C., for the Venlafaxine Study Group (1999) Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Primary Care Psychiatry, 5, 5763.
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington, DC: APA.
American Psychiatric Association (1993) Practice guideline for major depressive disorder in adults. American Journal of Psychiatry, 150 (suppl. 4): 126.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington, DC: APA.
Anderson, I. M. & Tomenson, B. M. (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Journal of Psychopharmacology, 8, 238249.
Ballús, C., Quiros, G., de Flores, T., et al (2000) The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. International Clinical Psychopharmacology, 15, 4348.
Beasley, C. M. Jr., Dornseif, B. E., Bosomworth, J. C., et al (1991) Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. British Medical Journal, 303, 685692.
Breslow, N. E. & Day, N. E. (1980) Statistical Methods in Cancer Research. Volume 1. The Analysis of Case–Control Studies. Lyons: IARC Scientific Publications.
Clerc, G. E., Ruimy, P., Verdeau-Paillès, J., et al (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. International Clinical Psychopharmacology, 9, 139143.
Costa e Silva, J. (1998) Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. Journal of Clinical Psychiatry, 59, 352357.
Depression Guideline Panel (1993) Depression in Primary Care. Volume 2. Treatment of Major Depression. Clinical Practice Guideline No. 5, AHCPR Publication No. 93-0551. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research.
DeRubeis, R. J., Gelfand, L. A., Tang, T. Z., et al (1999) Medication versus cognitive behavior therapy for severely depressed outpatients: meta-analysis of four randomized comparisons. American Journal of Psychiatry, 156, 10071013.
Diaz-Martinez, A., Benassinni, O., Ontiveros, A., et al (1998) A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clinical Therapeutics, 20, 467476.
Dierick, M., Ravizza, L., Realini, R., et al (1996) A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in Neuropsychopharmacology and Biological Psychiatry, 20, 5771.
Duman, R. S., Heninger, G. R. & Nestler, E. J. (1997) A molecular and cellular theory of depression. Archives of General Psychiatry, 54, 597606.
Edwards, J. G. & Anderson, I. (1999) Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs, 54, 507533.
Fava, G. A., Grandi, S., Zielezny, M., et al (1996) Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. American Journal of Psychiatry, 153, 945947.
Frank, E., Prien, R. F., Jarrett, R. B., et al (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry, 48, 851855.
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 5662.
Harvey, A. T., Rudolph, R. L. & Preskorn, S. H. (2000) Evidence of the dual mechanisms of action of venlafaxine. Archives of General Psychiatry, 57, 503509.
Leber, P. (1991) Is there an alternative to the randomized controlled trial? Psychopharmacology, Bulletin, 27, 38.
McPartlin, G. M., Reynolds, A., Anderson, C., et al (1998) A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Primary Care Psychiatry, 4, 127132.
Mehtonen, O.-P., Behnke, K., Søgaard, J., et al (2000) Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depression. Journal of Clinical Psychiatry, 61, 95100.
Miller, I. W., Keitner, G. I., Schatzberg, A. F., et al (1998) The treatment of chronic depression. Part 3: psychosocial functioning before and after treatment with sertraline or imipramine. Journal of Clinical Psychiatry, 59, 608619.
Montgomery, S. A. & Åsberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382389.
Muth, E. A., Haskins, J. T., Moyer, J. A., et al (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochemical Pharmacology, 35, 44934497.
National Institute of Mental Health (1985) Clinical Global Impressions. Psychopharmacology Bulletin, 21, 839843.
Owens, M. J., Morgan, W. N., Plott, S. J., et al (1997) Neurotransmitter receptor transporter binding profile of antidepressants and their metabolites. Journal of Pharmacology and Experimental Therapeutics, 283, 13051322.
Poirier, M.-F. & Boyer, P. (1999) Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. British Journal of Psychiatry, 175, 1216.
Prien, R. F., Carpenter, L. L. & Kupfer, D. J. (1991) The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Archives of General Psychiatry, 48, 796800.
Quitkin, F. M., Stewart, J. W., McGrath, P. J., et al (1993) Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. British Journal of Psychiatry, 163 (suppl. 21): 3034.
Redrobe, J. P., Bourin, M., Colombel, M. C., et al (1998) Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology, 138, 18.
Rothman, K. J. (1986) Modern Epidemiology. Boston, MA: Little, Brown & Co.
Rudolph, R. L. & Feiger, A. D. (1999) A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. Journal of Affective Disorders, 56, 171181.
Rudolph, R. L., Entsuah, R., Aguiar, L., et al (1998a) Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study. European Neuropsychopharmacology, 8 (suppl. 2), S142.
Rudolph, R. L., Fabre, L. F., Feighner, J. P., et al (1998b) A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Journal of Clinical Psychiatry, 59, 116122.
Salinas, E., for the Venlafaxine XR 367 Study Group (1997) Once-daily extended release (XR) venlafaxine versus paroxetine in outpatients with major depression. Biological Psychiatry, 42 (suppl. 1), 244S.
Silverstone, P. H., Ravindran, A., for the Venlafaxine XR 360 Study Group (1999) Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Journal of Clinical Psychiatry, 60, 2228.
Thase, M. E. (1998) Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. Journal of Clinical Psychiatry, 59, 502508.
Thase, M. E. (1999) How should efficacy be evaluated in randomized clinical trials of treatments for depression? Journal of Clinical Psychiatry, 60 (suppl. 4): 2332.
Thase, M. E., Simons, A. D., McGeary, J., et al (1992) Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. American Journal of Psychiatry, 149, 10461052.
Thase, M. E., Greenhouse, J. B., Frank, E., et al (1997) Treatment of major depression with psychotherapy or psychotherapy–pharmacotherapy combinations. Archives of General Psychiatry, 54, 10091015.
Tylee, A., Beaumont, G., Bowden, M. W., et al (1997) A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry, 3, 5158.
Tzanakaki, M., Guazzelli, M., Nimatoudis, I., et al (2000) Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. International Clinical Psychopharmacology, 15, 2934.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

  • Michael E. Thase (a1), A. Richard Entsuah (a2) and Richard L. Rudolph (a2)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *